GB0807451D0 - Inhibitors of PLK - Google Patents

Inhibitors of PLK

Info

Publication number
GB0807451D0
GB0807451D0 GBGB0807451.0A GB0807451A GB0807451D0 GB 0807451 D0 GB0807451 D0 GB 0807451D0 GB 0807451 A GB0807451 A GB 0807451A GB 0807451 D0 GB0807451 D0 GB 0807451D0
Authority
GB
United Kingdom
Prior art keywords
plk
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0807451.0A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chroma Therapeutics Ltd
Original Assignee
Chroma Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chroma Therapeutics Ltd filed Critical Chroma Therapeutics Ltd
Priority to GBGB0807451.0A priority Critical patent/GB0807451D0/en
Publication of GB0807451D0 publication Critical patent/GB0807451D0/en
Priority to US12/989,178 priority patent/US20110190306A1/en
Priority to PCT/GB2009/001019 priority patent/WO2009130453A1/en
Priority to JP2011505583A priority patent/JP2011518816A/ja
Priority to EP09735114A priority patent/EP2296662A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB0807451.0A 2008-04-24 2008-04-24 Inhibitors of PLK Ceased GB0807451D0 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GBGB0807451.0A GB0807451D0 (en) 2008-04-24 2008-04-24 Inhibitors of PLK
US12/989,178 US20110190306A1 (en) 2008-04-24 2009-04-23 Inhibitors of PLK
PCT/GB2009/001019 WO2009130453A1 (en) 2008-04-24 2009-04-23 Inhibitors of plk
JP2011505583A JP2011518816A (ja) 2008-04-24 2009-04-23 Ｐｌｋインヒビター
EP09735114A EP2296662A1 (en) 2008-04-24 2009-04-23 Inhibitors of plk

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0807451.0A GB0807451D0 (en) 2008-04-24 2008-04-24 Inhibitors of PLK

Publications (1)

Publication Number Publication Date
GB0807451D0 true GB0807451D0 (en) 2008-05-28

Family

ID=39494145

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0807451.0A Ceased GB0807451D0 (en) 2008-04-24 2008-04-24 Inhibitors of PLK

Country Status (5)

Country Link
US (1) US20110190306A1 (enExample)
EP (1) EP2296662A1 (enExample)
JP (1) JP2011518816A (enExample)
GB (1) GB0807451D0 (enExample)
WO (1) WO2009130453A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0803747D0 (en) * 2008-02-29 2008-04-09 Martin Enzyme and receptor modulation
GB0903480D0 (en) 2009-02-27 2009-04-08 Chroma Therapeutics Ltd Enzyme Inhibitors
CN102762568A (zh) * 2009-12-23 2012-10-31 伊兰药品公司 作为polo样激酶的抑制剂的蝶啶酮
GB201211310D0 (en) 2012-06-26 2012-08-08 Chroma Therapeutics Ltd CSF-1R kinase inhibitors
SI3222616T1 (sl) 2012-10-17 2019-10-30 Macrophage Pharma Ltd N-(2-(4-(6-amino-5-(2,4-difluorobenzoil)-2-oksopiridin-1(2H)-IL)-3,5- difluorofenil)etil)-L-alanin in njegov terbutil ester
JP6815318B2 (ja) * 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
GB201713975D0 (en) 2017-08-31 2017-10-18 Macrophage Pharma Ltd Medical use
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006021548A1 (de) * 2004-08-27 2006-03-02 Boehringer Ingelheim International Gmbh Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
BRPI0718120A2 (pt) * 2006-10-25 2013-11-12 Chroma Therapeutics Ltd Derivados de pteridina como inibidores de cinase do tipo pólo úteis no tratamento de câncer

Also Published As

Publication number Publication date
JP2011518816A (ja) 2011-06-30
WO2009130453A1 (en) 2009-10-29
EP2296662A1 (en) 2011-03-23
US20110190306A1 (en) 2011-08-04

Similar Documents

Publication Publication Date Title
ZA201000318B (en) Inhibitors of 11b-hydroxysteroid dehydrogenase
ZA201008808B (en) Novel phenylpyrazinones as kinase inhibitors
ZA201204246B (en) Kinase inhibitors
ZA201203842B (en) Kinase inhibitors
IL208136A0 (en) Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases
IL211693A0 (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
ZA201004942B (en) Ptrrolopyrazine kinase inhibitors
ZA201100898B (en) Novel inhibitors
SI2373157T1 (sl) Disperzije, ki vsebujejo inhibitorje hidroksifenilpiruvat-dioksigenaze
IL212119A0 (en) Alkylcyclohexylethers of dihydrotetraazabenzoazulenes
PL2133419T3 (pl) Zastosowania beta-dipeptydów cyjanoficyny
ZA201004765B (en) Inhibitors of iap
GB0621203D0 (en) PLK inhibitors
ZA201102837B (en) Phosphodiestarase inhibitors
IL208916A0 (en) Inhibitors of jnk
GB0916010D0 (en) JMJD2 demethylase inhibitors
GB0621205D0 (en) Inhibitors of PLK
GB0807452D0 (en) PLK inhibitors
GB0914726D0 (en) Kinase inhibitors
GB0715614D0 (en) Inhibitors of plk
GB201019387D0 (en) Inhibitors
GB0816125D0 (en) Novel inhibitors
GB0902661D0 (en) Inhibitors
GB0903650D0 (en) Glyoalase inhibitors
GB0915927D0 (en) Novel inhibitors

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)